Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population

Fundamental and Clinical Pharmacology

Volumn 21, Issue 4, 2007, Pages 411-418

  Jeannesson, Elise ^a   Albertini, Laetitia ^a   Siest, Gérard ^a   Gomes, Ana Margarida ^b   Ribeiro, Vera ^b   Aslanidis, Charalampos ^c   Schmitz, Gerd ^c   Visvikis Siest, Sophie ^a  

^a INSERM   (France)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

ABCB1; Haplotype; Polymorphism; Transporter

Indexed keywords

EDETIC ACID; MULTIDRUG RESISTANCE PROTEIN 1;

CONFERENCE PAPER; DNA ISOLATION; FRANCE; GENE FREQUENCY; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; NORMAL HUMAN; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ALLELES; FRANCE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 34447515970     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00507.x     Document Type: Conference Paper

References (33)

1. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75 13 33.
2. Siest G., Marteau J.B., Maumus S. et al. Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. Eur. J. Pharmacol. (2005) 527 1 22.
3. Luker G.D., Nilsson K.R., Covey D.F., Piwnica-Worms D. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J. Biol. Chem. (1999) 274 6979 6991.
4. Garrigues A., Escargueil A.E., Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc. Natl. Acad. Sci. U.S.A. (2002) 99 10347 10352.
5. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. (2006) 112 457 473.
6. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug. Deliv. Rev. (2002) 54 1295 1310.
7. Okamura N., Sakaeda T., Okumura K. Pharmacogenomics of MDR and MRP subfamilies. Personal. Med. (2004) 1 85 104.
8. Pauli-Magnus C., Kroetz D.L. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res. (2004) 21 904 913.
9. Brant S.R., Panhuysen C.I., Nicolae D. et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet. (2003) 73 1282 1292.
10. Hoffmeyer S., Burk O., von Richter O. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. (2000) 97 3473 3478.
11. Kajinami K., Brousseau M.E., Ordovas J.M., Schaefer E.J. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol. (2004) 93 1046 1050.
12. Siest G., Visvikis S., Herbeth B. et al. Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin. Chem. Lab. Med. (1998) 36 35 42.
13. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. (1988) 16 1215.
14. Cavaco I., Gil J.P., Gil-Berglund E., Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. (2003) 41 1345 1350.
15. Tanabe M., Ieiri I., Nagata N. et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297 1137 1143.
16. Tregouet D.A., Barbaux S., Escolano S. et al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum. Mol. Genet. (2002) 11 2015 2023.
17. Anglicheau D., Thervet E., Etienne I. et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. (2004) 75 422 433.
18. Allabi A.C., Horsmans Y., Issaoui B., Gala J.L. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur. J. Clin. Pharmacol. (2005) 61 97 102.
19. Goto M., Masuda S., Saito H. et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 12 451 457.
20. Kroetz D.L., Pauli-Magnus C., Hodges L.M. et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 13 481 494.
21. Ameyaw M.M., Regateiro F., Li T. et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 11 217 221.
22. Tan E.K., Drozdzik M., Bialecka M. et al. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci. Lett. (2004) 372 240 244.
23. Ho G.T., Nimmo E.R., Tenesa A. et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology (2005) 128 288 296.
24. Bernal M.L., Sinues B., Fanlo A., Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. (2003) 25 107 111.
25. Furuno T., Landi M.T., Ceroni M. et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics (2002) 12 529 534.
26. Pechandova K., Buzkova H., Slanar O., Perlik F. Polymorphisms of the MDR1 gene in the Czech Population. Folia Biol. (Praha) (2006) 52 184 189.
27. Cascorbi I., Gerloff T., Johne A. et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 69 169 174.
28. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. (2003) 59 303 312.
29. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics (2005) 15 693 704.
30. Kim R.B., Leake B.F., Choo E.F. et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 70 189 199.
31. Tang K., Ngoi S.M., Gwee P.C. et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics (2002) 12 437 450.
32. Kurzawski M., Pawlik A., Gornik W., Drozdzik M. Frequency of common MDR1 gene variants in a Polish population. Pharmacol. Rep. (2006) 58 35 40.
33. Lamba J., Strom S., Venkataramanan R. et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther. (2006) 79 325 338.